BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21514924)

  • 1. Cognitively preserved subjects with transitional cerebrospinal fluid ß-amyloid 1-42 values have thicker cortex in Alzheimer's disease vulnerable areas.
    Fortea J; Sala-Llonch R; Bartrés-Faz D; Lladó A; Solé-Padullés C; Bosch B; Antonell A; Olives J; Sanchez-Valle R; Molinuevo JL; Rami L
    Biol Psychiatry; 2011 Jul; 70(2):183-90. PubMed ID: 21514924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSEN1 mutation carriers present lower cerebrospinal fluid amyoid-β42 levels than sporadic early-onset Alzheimer's disease patients but no differences in neuronal injury biomarkers.
    Balasa M; Vidal-Piñeiro D; Lladó A; Antonell A; Bosch B; Castellanos F; Bargalló N; Bartres-Faz D; Molinuevo JL; Sánchez-Valle R
    J Alzheimers Dis; 2012; 30(3):605-16. PubMed ID: 22426017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive reserve proxies relate to gray matter loss in cognitively healthy elderly with abnormal cerebrospinal fluid amyloid-β levels.
    Arenaza-Urquijo EM; Molinuevo JL; Sala-Llonch R; Solé-Padullés C; Balasa M; Bosch B; Olives J; Antonell A; Lladó A; Sánchez-Valle R; Rami L; Bartrés-Faz D
    J Alzheimers Dis; 2013; 35(4):715-26. PubMed ID: 23481686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease.
    Fortea J; Vilaplana E; Alcolea D; Carmona-Iragui M; Sánchez-Saudinos MB; Sala I; Antón-Aguirre S; González S; Medrano S; Pegueroles J; Morenas E; Clarimón J; Blesa R; Lleó A;
    Ann Neurol; 2014 Aug; 76(2):223-30. PubMed ID: 24852682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
    Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
    Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
    J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum.
    Solé-Padullés C; Lladó A; Bartrés-Faz D; Fortea J; Sánchez-Valle R; Bosch B; Antonell A; Molinuevo JL; Rami L
    Psychiatry Res; 2011 Jun; 192(3):140-6. PubMed ID: 21546220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
    Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grey matter and cognitive patterns in cognitive impaired subjects using CSF biomarker cut-offs.
    Miralbell J; Spulber G; Hooshmand B; Besga A; Mataró M; Cedazo-Minguez A; Kivipelto M; Wahlund LO
    J Alzheimers Dis; 2012; 29(4):741-9. PubMed ID: 22330819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
    Fagan AM; Mintun MA; Mach RH; Lee SY; Dence CS; Shah AR; LaRossa GN; Spinner ML; Klunk WE; Mathis CA; DeKosky ST; Morris JC; Holtzman DM
    Ann Neurol; 2006 Mar; 59(3):512-9. PubMed ID: 16372280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased cortical thickness and caudate volume precede atrophy in PSEN1 mutation carriers.
    Fortea J; Sala-Llonch R; Bartrés-Faz D; Bosch B; Lladó A; Bargalló N; Molinuevo JL; Sánchez-Valle R
    J Alzheimers Dis; 2010; 22(3):909-22. PubMed ID: 20858974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
    Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
    Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
    Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
    J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
    Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
    J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid beta 1-42 in cerebrospinal fluid is associated with cognitive plasticity.
    Uttner I; Schurig N; von Arnim CA; Lange-Asschenfeldt C; Brettschneider J; Riepe MW; Tumani H
    Psychiatry Res; 2011 Nov; 190(1):132-6. PubMed ID: 21620485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.